Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
ABEYE
Cleveland, Ohio, United Statesabeye.tech ↗
- Ownership
- Private
- Employees
- ~136
- Development stage
- Commercial
01
Overview
Abeona’s lead clinical candidate pz-cel/EB‑101 is an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa and has reached Phase 3 development. The company also has a pipeline of preclinical and early clinical AAV-based gene therapies targeting rare ophthalmic and neurodegenerative diseases.
- Therapeutic areas
- Rare DiseasesDermatologyOphthalmologyNeurology
- Modalities
- Cell therapyGene therapyAdeno-associated virus-based gene therapy
- Industry
- Biotech
02
Partnerships
Ultragenyx Pharmaceutical Inc.Taysha Gene Therapies Inc.University of North Carolina at Chapel Hill
Beyond the preview
Go deeper on ABEYE.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABEYE.